Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)

Authors
Category Primary study
Year 2013
This article has no abstract
Epistemonikos ID: 2cfeb7951fb0b25b16838dc4954ffa5328326eec
First added on: Jun 08, 2018